Serum metabolomics study for acute attack of chronic pancreatitis

• DOI: 10.1016/j.cca.2023.117251
• Publication Date: 2023-02-10T21:41:26Z
• Authors: Ling Wu; Xiangping Huang; Qianhui Ouyang; Wen Liu; Sixiang Liu; Ying Huang; Ya Peng; Ding Ning; Chaochao Tan
• Keywords: Diglycerides; 0303 health sciences; 03 medical and health sciences; Pancreatitis, Chronic; Humans; Metabolomics; Prospective Studies; Biomarkers; 3. Good health

Chronic pancreatitis (CP) is an inflammatory disease characterized by irreversible changes. However, acute CP attacks can lead to various complications and affect patient prognosis. Therefore, this study aimed to identify reliable candidate metabolic biomarkers for diagnosing acute CP attacks and complement candidate diagnostic markers for CP.A total of 139 serum specimens were prospectively included in three consecutive exploratory, identification, and validation studies. All samples were analyzed for candidate diagnostic biomarkers and metabolic pathways using a liquid chromatography-mass spectrometer.Serum metabolic profiles differed between patients with CP and non-pancreatic disease controls, and 239 potential metabolic biomarkers for diagnosing CP were identified. Based on identification and validation studies, Diacylglycerol(16:0/18:4), 16-F1-PhytoP, N-(hexacosanoyl)-tetradecasphing-4-enine, carnosic acid, and Auxin b were identified as biomarkers for distinguishing acute attacks from non-acute attacks in patients with CP. The area under the curve of the Diacylglycerol(16:0/18:4) was 0.969 (95% confidence interval, 0.869-1) in the validation study.To the best of our knowledge, this is the first prospective cohort study to identify and validate a metabolomic signature in serum for diagnosing acute attacks of CP. In addition, our study identified 239 potential biomarkers for CP diagnosis.